Communiqués Rezolute, Inc.

Actions

RZLT

US76200L3096

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:33:28 21/09/2026			Varia. 5j.	Varia. 1 janv.
3,865 ^USD	+0,65%		-10,24%	+61,65%

09/09	Rezolute indique que la FDA examine toujours les données d'ersodetug issues de l'étude de phase 3 sur l'hyperinsulinisme congénital	MT
09/09	Rezolute fait le point sur l'examen par la FDA des résultats de son étude de phase 3 Sunrize dans l'hyperinsulinisme congénital	CI

Communiqués

09/09	Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism	GL
02/09	Rezolute to Participate in Upcoming Investor Conferences	GL
21/07	Rezolute to Participate in the BTIG Virtual Biotechnology Conference	GL
17/06	Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society	GL
04/06	Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society	GL
02/06	Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism	GL
12/05	Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update	GL
11/05	Rezolute to Participate in Upcoming Investor Conferences	GL
01/05	Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting	GL
21/04	Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting	GL
24/03	Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting	GL
05/03	INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)	PR
04/03	Rezolute to Participate in the Citizens Life Sciences Conference	GL
28/02	RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	PR
24/02	RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	NE
21/02	Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	NE
18/02	INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	NE
13/02	INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	PR
12/02	Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update	GL
10/02	SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	NE
05/02	SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	NE
04/02	Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026	GL
31/01	SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	NE
29/01	SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	PR
27/01	SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute	NE